Lung cancer is the most-common cancer worldwide, with an estimated 1.8 million cases diagnosed each year and an estimated 1.6 million lung-cancer-related deaths annually 1,2 . Globally, small-cell lung cancer (SCLC) accounts for 13-15% of all lung cancers, with approximately 250,000 cases diagnosed annually, and is the sixth most-common cause of cancer-related mortality [3] [4] [5] [6] [7] . SCLC is an aggressive high-grade neuroendocrine tumour associated with a short doubling time, a high growth fraction, and early development of widespread metastases, which contribute to the extremely poor prognosis of patients with the disease. The typical life expectancy for a patient diagnosed with SCLC, and the standard options for therapy, have not changed over the past three decades (FIG. 1) ; the median overall survival duration of patients with extensive-stage (ES)-SCLC is stalled, frustratingly, at <10 months, with a discouraging 5-year overall survival of 1-5% 4 . The incidence of SCLC in the developed world has decreased in parallel with the declining rates of smoking, although SCLC remains a substantial cause of cancer-related mortality worldwide 2, 8 . Among the major lung-cancer subtypes, SCLC has the strongest association with smoking, with only 2% of cases occurring in never-smokers 9,10 . Consequently, SCLCs have a high load of somatic mutations induced by tobacco carcinogens [11] [12] [13] . The most common genetic alterations in SCLC include inactivation of the tumour-suppressor genes TP53 and RB1, as well as copy-number gains of genes encoding MYC family members, enzymes involved in chromatin remodelling, receptor tyrosine kinases and their downstream effectors, and Notch family proteins 12, 13 . Importantly, the high mutational burden of SCLC might provide opportunities for therapeutic intervention. In this Review, we explore the progress made in defining the molecular aetiology of SCLC and discuss the development of rational therapeutic strategies based on the disease biology.
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Clinical overview
Pathology. SCLC is one constituent of a group of neuroendocrine lung tumours that also includes large-cell neuroendocrine carcinoma, and typical and atypical carcinoid tumours. The diagnosis of SCLC is based primarily on histological appearance by light microscopy, demonstrating dense sheets of small cells with neuroendocrine differentiation (characterized by scant cytoplasm; poorly defined cell borders; dispersed, finely granular nuclear chromatin; absent or inconspicuous nucleoli; and prominent nuclear moulding). Necrosis is typically extensive and the mitotic count is exceptionally high (>10 mitoses per 10 high-power fields), with a high Ki67 labelling index (using the MIB-1 antibody) of around 90-100% also indicating rapid cell proliferation 14 . Current classifications of SCLC subtypes include 'small-cell carcinoma' and 'combined smallcell carcinoma' , with the latter comprising small-cell carcinomas harbouring an additional component of nonsmall-cell carcinoma (NSCLC), such as adeno carcinoma, squamous-cell carcinoma, or large-cell carcinoma 14 . Combined small-cell carcinoma accounts for approximately 10-25% of SCLC cases. Most SCLCs express the neuroendocrine markers CD45, CD56, chromogranin, and synaptophysin; fewer than 10% of SCLCs are negative for all neuroendocrine markers 14 . SCLC can be staged according to the conventional 'TNM' criteria, as defined by the Union for International Cancer Control and the American Joint Committee on Cancer 4 . Surgery can have a role in the treatment of patients with early, TNM stage I disease (tumours <5 cm in diameter with no lymph-node involvement or metastasis); however, disease presentation at such early stage is the exception to the norm. More commonly, SCLC is staged as limited-stage or extensive-stage disease; these distinctions are both prognostic and guide the use of the available treatment options.
Limited-stage disease. Limited-stage (LS)-SCLC is defined as disease confined to a single radiation port (that is, to a tolerable treatment field), with or without mediastinal lymph-node involvement. Only around one-third of patients diagnosed with SCLC present with LS-SCLC. In contrast to NSCLC, low-dose CT screening has not been shown to improve the survival of patients with SCLC, or to increase the number of patients diagnosed with early stage disease 15 . Treatment advances involving thoracic and cranial irradiation have led to improved outcomes for patients with LS-SCLC 6 (FIG. 1) . The rapid proliferation rate of this malignancy confers an exquisite sensitivity to DNA-damaging therapies; thus, the standard of care for LS-SCLC is concurrent chemoradiotherapy with cisplatin and etoposide, which results in an objective response rate (ORR) of 70-90% 16 , and has been associated with 44% survival at 2 years and 23% survival at 5 years 17, 18 . The radiotherapy regimen best supported by randomized clinical trial data is 45 Gy delivered in 30 twice-daily (b.i.d.) 1.5-Gy fractions (over 3 weeks) 17 . In this practice-defining study 17 , however, the b.i.d. fractionation schema was compared with a regimen comprising the same nominal dose of 45 Gy delivered in 25 once-daily 1.8-Gy fractions (over 5 weeks), which is not a biologically equivalent dose. Accordingly, in the ongoing EORTC 08072 CONVERT trial (NCT00433563) and the CALGB 30610/RTOG 0538 trial (NCT00632853), the standard b.i.d. regimen is being compared to biologically equivalent doses: once-daily 2-Gy fractions to a total dose of 66 Gy and 70 Gy, respectively (over 6.5-7 weeks). Early results of the CONVERT trial, presented in abstract form at the ASCO 2016 meeting 19 , indicate equivalent overall survival and toxicity between the two arms, providing some evidence to support the use of either regimen.
The blood-brain barrier can restrict access of systemically delivered therapies into the brain and, therefore, most patients with LC-SCLC experience recurrent disease in the central nervous system (CNS). Thus, prophylactic cranial irradiation (PCI) is recommended for patients with LS-SCLC who respond to upfront con current chemoradiotherapy and have no evidence of brain metastasis on MRI, in order to eliminate undetectable micrometastatic disease that might be present 20 . Results of a large meta-analysis have confirmed the survival benefit of this approach 21 . In summary, the preferred therapeutic strategy for patients with LS-SCLC is concurrent chemoradiotherapy (with cisplatin and etoposide) 16 , followed by PCI in those who achieve complete remission 21 ; the associated 5-year survival ranges from 20-40% depending on disease stage and degree of nodal involvement 22 .
Extensive-stage disease. ES-SCLC, defined as disease that has spread beyond a single radiation port (generally synonymous with distant metastasis), accounts for two-thirds of all SCLC diagnoses 6, 23 . As described previously, the outcomes of patients with ES-SCLC are dismal, with median overall survival durations of <10 months and 5-year survival <5% 4 . First-line treatment for such patients, which has remained unchanged for more than three decades (FIG. 1) , generally consists of 4-6 cycles of chemotherapy with a platinum-based agent (either cisplatin or carboplatin) and etoposide. ORRs associated with this regimen approach 70%; however, most patients suffer rapid disease relapse within 6 months [24] [25] [26] [27] [28] [29] [30] . The use of a platinum-based drug in combination with irinotecan is also an acceptable first-line treatment, and this regimen is commonly used in Japan 28, 29 . Results of the largest North American study reported to date 31 , however, did not confirm the clinical benefit of cisplatin and irinotecan versus cisplatin and etoposide previously reported in Japanese cohorts 28, 29 . Despite the inevitable and rapid disease relapse after first-line treatment, topotecan is the only systemic therapy approved by the FDA for the treatment of recurrent ES-SCLC. Furthermore, the activity of this agent is, in general, limited to patients with chemosensitive relapse, defined as those with an objective response to first-line chemotherapy that persisted for at least 3 months after completion of therapy 32 . Unfortunately, the mechanisms of acquired chemoresistance in SCLC are poorly understood.
The roles of thoracic radiation therapy and PCI in the treatment of ES-SCLC remain controversial. A randomized phase III trial of post-chemotherapy consolidative chest radiation was negative for its primary end point of an improvement in overall survival at 1 year compared with that observed without thoracic radiotherapy (33% versus 28%; P = 0.066), but results of a post-hoc analysis indicated an overall survival benefit at 2 years (13% versus 3%; P = 0.004) 33 . A survival benefit from consolidative thoracic radiotherapy was also later reported for the subgroup of patients with residual intrathoracic disease (HR 0.81, 95% CI 0.66-1.00; P = 0.044) 34 . The low-dose radiation regimen used (30 Gy in 10 fractions) was well tolerated, with no marked differences in toxicities between the control and experimental groups 33 . Further work is necessary to confirm these results, and to identify additional subsets of patients with ES-SCLC who are most likely to benefit from consolidative thoracic radiotherapy. Of note, all patients included in this study received PCI 33 . PCI has been reported to improve the overall survival of patients with ES-SCLC (27.1% at 1 year versus 13.3% without PCI), but in a study in which radiological assessment before PCI was not mandated 35 ; thus, the inclusion of patients with overt brain meta stases might have contributed to the apparent clinical benefit. Indeed, in a more-recent Japanese phase III trial 36 , in which pretreatment brain imaging was mandated to exclude patients with detectable brain meta stases, PCI did not improve the overall survival of patients with ES-SCLC. Of note, both patients and physicians have concerns regarding the potential for delayed PCI-related neurotoxicity, which must be balanced with the need to achieve disease control 37, 38 . Essentially, the management of ES-SCLC has remained unchanged for the past 20 years -since the approval of topotecan for recurrent and/or refractory disease in 1996 (FIG. 1) -and effectiveness of the few available treatment options is limited; therefore, novel, targeted, and biomarker-guided therapies are an important unmet need. Advances in genomic, epigenetic, and proteomic profiling, tumour immunology, and tumour biology have led to exciting new experimental therapies, some of which have been shown to provide a meaningful clinical benefit in early phase clinical trials. In the following sections, we discuss the breakthroughs in our understanding of the molecular and cellular biology of SCLC, and highlight the emerging targets for novel treatments.
SCLC developmental regulatory pathways
SCLCs display poorly differentiated neuroendocrine features 14 ; three distinct molecular subtypes have been defined by gene-expression profiles determined by differential expression of the neuronal basic helixloop-helix transcription factors achaete-scute homologue 1 (ASCL1, also known as ASH-1) and neurogenic differentiation factor 1 (NEUROD1) [39] [40] [41] . A subgroup defined by expression of ASCL1 has been described as the 'classic' subtype, while a subgroup defined by high expression levels of NEUROD1 has been described as the 'variant' subtype [41] [42] [43] . The third, minor subgroup lacks expression of either of these neuroendocrine markers. These subgroups are clearly distinct disease entities based on gene-expression profiling, although the clinical implications of this molecular classification have not been defined -for example, whether these subtypes have differential capacities for invasion or metastasis, or differential responses to standard therapies is unknown.
In a genetically engineered mouse model, conditional Cre-mediated excision of the Tp53 and Rb1 gene in lung epithelial cells gives rise to lung tumours resembling the classic subtype of SCLC 44 . Interestingly, tumours resembling variant subtype SCLC are not observed in this model 45 . The results of subsequent experiments have revealed that ASCL1 activates pulmonary neuro endocrine differentiation 46 ; regulates the expression of multiple Notch-pathway genes, including the gene encoding the inhibitory Notch ligand Delta-like protein 3 (DLL3) 39 ; and is required for tumour initiation in this model, whereas NeuroD1 is dispensable 47, 48 . In 2017, however, Mollaoglu et al. 49 demonstrated that over expression of an oncogenic Myc T58A allele in this context promotes the development of 'neuroendocrine-low' tumours resembling variant subtype SCLC, characterized by a high level of NeuroD1 expression and low ASCL1 expression levels. Importantly, a targeted drug screen in this model revealed the therapeutic potential of aurora kinase inhibitors, in combination with cisplatin and etoposide chemotherapy, in MYC-driven, variant-subtype SCLC 49 . ASCL1 drives the expression of many proto-oncogenes implicated in SCLC progression and cell survival, including MYCL1, RET, SOX2, NF-IB, and BCL2 (REFS 39, 50) . Although NEUROD1 does not seem to be required for the tumorigenesis of classic subtype SCLC, this transcription factor has been shown to induce migratory signalling pathways in human SCLC cells 51 , and can activate a neuroendocrine differentiation programme in a mouse lung epithelial (non-neuroendocrine) cell line 52 .
The SCLC genome, epigenome, and proteome Genetic landscape. SCLC cells are typically aneuploid, with a high incidence of chromosomal deletions of 3p, 4q, 5q, 10q, 13q, and 17p, and copy-number gains of 3q, 5p, 6p, 8q, 17q, 19, and 20q . The genetic mutational landscape of SCLC is complex and varied, but functional inactivation of both TP53 and RB1 is essentially universal 12, 13 . Other molecular abnormalities detected in SCLCs include amplification and overexpression of MYC-family oncogenes 56 , overexpression of BCL2 (REF. 57 ) and KIT 58 , as well as activation of autocrine loops through bombesin-like peptides 59 . Gene-expression profiling data suggest that several neuroendocrine genes are expressed in SCLCs, including those encoding chromogranins A, B, and C (CHGA, CHGB, and CHGC (SCG2)) 60 , insulinoma-associated gene 1 (INSM1) 61 , as well as ASCL1 (REF. 62 ); however, the relevance of many of these markers, with respect to improving the diagnosis or in directing therapy for the disease, remains unclear.
In the past 5 years, comprehensive genomic studies, including exome, whole-genome, transcriptome, and copy-number alteration analyses of primary human SCLC samples, have provided the first overview of genomic landscape of this disease 12, 13, 63, 64 . SCLCs have a mean mutation rate of 7.4 nonsynonymous mutations per million base pairs -similar to that of other tobacco-associated lung cancers 12, 65 . As noted, biallelic inactivation of TP53 and RB1 is near-ubiquitous in SCLC 12, 13, 63, 64 . Recurrent mutations in CREBBP, EP300, MLL (also known as KMT2A), PTEN, SLIT2, EPHA7, and NOTCH genes, and amplification of FGFR1 and SOX2, have also been reported 12, 13, 63 . In particular, mutations affecting Notch proteins have been detected in 25% of SCLCs, and these receptors have been validated as tumour suppressors in mouse models of SCLC 12 . Indeed, alterations in tumour-suppressor genes were the most-frequent finding in SCLC samples. Lastly, RNA-sequencing data have identified multiple fusion transcripts in primary SCLC specimens, including a recurrent RLF-MYCL1 fusion 13 . Further work is needed to better understand how individual genomic alterations associated with SCLC relate to patient response to therapy and outcome.
Epigenetic landscape. Epigenetic processes have a central role in carcinogenesis, and tumour maintenance, progression, and responses to treatment 66 . Most early cancer epigenetics studies focused on DNA methylation at CpG-dinucleotide islands 67, 68 . DNA-methylation patterns are associated with gene expression, and promoter hypermethylation has been shown to lead to a hetero chromatin state and repressed gene expression 69 . Repression of tumour-suppressor genes and genes required for programmed cell death in this manner, as well as derepression of oncogenes, can provide a fitness advantage for cancer cells 67, 68 . Evidence for this paradigm in SCLC was provided by the finding that several SCLC cell lines were insensitive to TNF-related apoptosisinducing ligand (TRAIL)-mediated apoptosis owing to epigenetic silencing of genes encoding caspase-8, FAS, and TRAIL-R1 via promoter CpG-island methylation 70 . Interestingly, treatment with the DNA methyl transferase (DNMT) inhibitor decitabine, in combination with IFNγ (which has been shown to upregulate expression of caspase-8), partially restored caspase-8 expression and increased the sensitivity of the SCLC cell lines to TRAIL-induced apoptosis 70 . Subsequently, the combination of DNMT inhibition using decitabine and histone deacetylase (HDAC) inhibition using either valproic acid or CI-994 could restore expression of caspase-8, sensitizing the cell lines to TRAIL-mediated cell death 71 . These findings provide insight into the mechanisms by which DNA-methylation events can impair the extrinsic apoptosis pathway and provided early evidence of the potential for pharmacological reversibility of such events in SCLC cells.
In the first genome-scale analysis of methylation changes in SCLC 72 , 73 genes that were methylated in >77% of SCLC tumours were identified. Methylated gene promoters were enriched in binding sites for the neurogenic transcription factors NEUROD1, heart and neural crest derivatives-expressed protein 1 (HAND1), zinc finger protein 423 (ZNF423), and RE1-silencing transcription factor (REST), which the authors interpreted as being indicative of a defect in neuroendocrine differentiation 72 . Results of a subsequent genome-wide study, performed at single-nucleotide resolution, demonstrated overall DNA hypomethylation in primary SCLC samples compared with non-neoplastic lung specimens; however, CpG-island-containing promoters were found to be hypermethylated in SCLC to a greater degree than most tumour types included in The Cancer Genome Atlas 40 . Hypermethylated sites were concentrated focally at transcription start sites, whereas hypomethylated sites were distributed diffusely throughout promoter regions, suggesting a functional role for hyper methylation in cancer-specific gene silencing 40 . The authors further demonstrated that a major subgroup of SCLC has increased promoter methylation in a manner similar to what has been described in other tumour types as the 'CpG-island methylator phenotype' (CIMP) 40 . Of note, the CIMP has been associated with an un favourable prognosis across multiple tumour types 73, 74 . Neither initial genome-scale study in SCLC reported relationships of methylation profiles with patient outcome data 40, 72 . In an ensuing study, however, SCLC samples could be similarly stratified according to CIMP status, and patients with CIMP-positive tumours had a poorer prognosis than those with CIMP-negative disease 75 . These data suggest that clinically relevant subtypes of SCLC are defined by DNA-methylation patterns, consistent with observations among other lung carcinoma epitypes 74 .
Proteomic landscape. Proteomic and transcriptomic analyses of 34 SCLC and 74 NSCLC cell lines revealed a number of proteins of potential therapeutic interest that are differentially expressed between these tumour types 76 . In comparison to NSCLCs, SCLCs had substantially increased levels of the growth-factor receptor KIT; the antiapoptotic protein Bcl-2, and the pro-apoptotic Bcl-2 family members BIM (Bcl-2-like protein 11) and BAX (Bcl-2-like protein 4); histone-lysine N-methyltransferase EZH2 (also known as enhancer of zeste homologue 2), a chromatin-remodelling factor; thymidylate synthase; and DNA-repair proteins, including poly [ADP-ribose] polymerase (PARP) enzymes 76 .
Potential therapeutic targets in SCLC Many of the new insights into the biology of SCLC are now being actively translated into clinical trials of novel treatments for patients with this disease. In the following sections of this Review, we highlight some of the particularly attractive targets for clinical investigation.
PARP inhibitors. PARP enzymes were first identified in 1963 (REF. 77 ). To date, 17 structural PARP enzymes have been described 78 . PARP1 -the most abundantly expressed isoform in humans -and PARP2 function to detect and mark DNA single-strand breaks (SSB) by binding to the site of DNA damage and synthesizing poly [ADP-ribose] chains, which recruit a host of scaffold proteins and DNA-repair enzymes to mend the break 79 . As alluded to, PARP protein levels are upregulated in SCLC relative to other lung cancers 76 . In particular, PARP1 has been found to be highly expressed at both the mRNA and protein levels in SCLC samples 76 . In addition to DNA repair, this protein is a co-activator of the transcription factor E2F1 (FIG. 2) , and has been implicated in various cellular processes involved in tumorigenesis -including cell differentiation, proliferation, and transformation 80 . The results of initial in vitro studies indicated that SCLC cell lines are sensitive to PARP inhibitors, and provided preclinical validation that PARP inhibition enhances the anticancer activity of chemotherapy (and perhaps other DNA-damaging therapies) by downregulating key DNArepair mechanisms 76 . These preclinical data supported the inclusion of a cohort of patients with SCLC in a phase I study of monotherapy with the PARP inhibitor talazoparib; the reported ORR was 9% and the clinical benefit rate at ≥16 weeks was 26% 81 . Clinical trials of a number of PARP inhibitors, in a range of treatment settings, are ongoing in patients with SCLC (TABLE 1) .
Various PARP inhibitors have received FDA approval or a 'breakthrough therapy' designation for the treatment of patients with ovarian cancer harbouring deleterious BRCA1 or BRCA2 mutations 82, 83 . BRCA1/2 are critical mediators of the DNA double-strand break repair pathway involving homologous recombination (HR). HR-deficient (HRD) tumour cells depend on PARP-mediated SSB-repair pathway 84, 85 , as well as other back-up pathways involving RAD52 (REFS 86, 87) and DNA polymerase θ, for survival 88, 89 . This synthetic lethal dependency can be exploited thera peutically; thus, PARP inhibition leads to selective lethality of BRCA1/2-mutated tumour cells. However, BRCA1/2 mutations are notably rare in primary human SCLCs, occurring in <2% of cases 12, 13 . Beyond BRCA1/2 mutations, HRD can be assessed using allele specific copy-number analysis of data generated from single-nucleotide polymorphism (SNP) microarrays and next-generation sequencing (NGS) approaches that quantify the resultant characteristic large-scale chromo somal aberrations 90 , and which have been shown to predict PARP inhibitor sensitivity in patients with BRCA1/2-wild-type ovarian cancer 91 . Surprisingly, however, HRD-assay scores do not seem to correlate with sensitivity to PARP inhibitors in SCLC cell lines 92 . A distinct mechanism, high expression levels of schlafen family member 11 (SLFN11), has been identified as a critical determinant of PARP-inhibitor sensitivity in SCLC cell lines and patient-derived xenografts 92, 93 . SLFN11 is actively recruited to sites of DNA damage, inhibits HR 94 , and activates a cellular replication-stress response 93 . Notably, SLFN11 expression correlates with sensitivity to DNA-damaging agents (such as iri notecan, etoposide, and cisplatin) in other malignancies [95] [96] [97] [98] . In line with the preclinical evidence 92 , high levels of SLFN11 expression (H-score ≥1) was associated with favourable tumour responses, progression-free survival (PFS), and overall survival in patients with SCLC who were treated with temozolomide and the PARP inhibitor veliparib, but not temozolomide plus placebo, in a randomized phase II clinical trial 99 . Of note, SLFN11 expression levels were defined using tumour samples obtained at initial diagnosis, and all patients enrolled had received at least one prior treatment 99 , which could have led to downregulation of SLFN11 at the time of study treatment; thus, this population might not have had ideal responses to PARP inhibition. Indeed, mechanisms to upregulate SLFN11 in chemoresistant patients are currently being considered. The utility of SLFN11 expression as a predictive biomarker for PARP-inhibitor therapy in SCLC will require validation in prospective biomarker-stratified trials.
EZH2 inhibition. The polycomb repressor complex 2 (PRC2) is a multiprotein chromatin-modifying complex that inhibits gene expression by promoting local histone
methylation. EZH2 is the enzymatic histone-lysine N-methyltransferase subunit of PRC2, and mediates histone H3 lysine 27 dimethylation and trimethylation (H3K27me2 and H3K27me3) 100 (FIG. 2) . EZH2 is mutated in some human cancers at gain of function hotspots that increase its enzymatic activity and thereby promote H3K27me3 (REF. 101 ). EZH2 is not commonly mutated in SCLC, but the level of EZH2 expression is higher in SCLCs than in any tumour type included in The Cancer Genome Atlas 40, 76 . Expression of the EZH2 gene is under the direct control of E2F family of transcription factors, including E2F1 (REF. 102 ) (for which PARP1, itself overexpressed in SCLC cells 76 , acts a co-activator). E2F transcriptional activity is negatively regulated by the product of the RB1 tumour-suppressor gene (Rb); the nearly universal loss of RB1 -and thus functional Rb -in SCLC cells results in a high level of E2F transcriptional activity, and consequent high EZH2 expression levels 103 . These observations define a model in which EZH2 expression is primarily promoted by one of the pathognomonic genetic alterations of SCLC (FIG. 2) .
In 2017, findings from multiple patient-derived xenografts linked the upregulation of EZH2 with H3K27me3-associated SLFN11 gene silencing as a frequent mechanism of acquired chemoresistance in SCLC 104 . EZH2-mediated suppression of SLFN11 was observed in 40% of SCLC models selected in vivo for acquired chemotherapeutic resistance 104 . Mechanistically, loss of SLFN11 expression increases HR efficiency and, therefore, augments repair of DNA damage induced by cytotoxic chemotherapy. Importantly, EZH2 inhibition was found to prevent SLFN11 silencing and maintain the sensitivity of SCLC xenografts to chemotherapy 104 , suggesting a potential combinatorial strategy to enhance the effectiveness of current standard therapies for this recalcitrant disease. Various EZH2 inhibitors are undergoing clinical testing in the treatment of a range of malignancies; although clinical trials enrolling patients with SCLC are a research priority, at present, no such studies are underway.
WEE1-targeted cell-cycle vulnerabilities.
The protein product of TP53, p53, has a critical role in the DNAdamage-response network, inducing cell-cycle arrest and initiation of apoptosis in cells exposed to genotoxic stress. Accordingly, TP53 deficiency leads to defective cell-cycle arrest at the G1/S checkpoint (FIG. 2) , blunts the DNA-damage response, and contributes to replication stress [105] [106] [107] . In SCLC cells, combined loss of RB1 and TP53 result in markedly defective G1/S cellcycle checkpoint capacity and, consequently, increased dependency on the G2/M checkpoint for adequate DNA repair and ultimately cell survival; rational targeting of the G2/M checkpoint might exploit this tumour-specific vulnerability 107 . The tyrosine kinase WEE1 is an important gatekeeper of the G2/M checkpoint (FIG. 2) , and induces G2 arrest via inhibitory phosphorylation of cyclin-dependent kinases 1 and 2 (REF. 108 ). The combination of a WEE1 inhibitor with any of several classes of DNA-damaging agents, including antimetabolites (gemcitabine or PD-L1) , and/or cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) can prime the adaptive immune response to SCLC cells, whereas antibody-mediated blockade of the 'don't eat me' protein CD47 can enable phagocytosis of tumour cells by macrophages. The use of small-molecule inhibitors of key regulators of the cell cycle, such as the protein kinases WEE1 and aurora kinase A, exploits the inherent lack of the G1/S-checkpoint activity resulting from loss of the tumour suppressors p53 and retinoblastoma-associated protein (Rb) in most SCLC cells. WEE1 regulates the G2/M cell-cycle checkpoint that is essential for ensuring the integrity of the genome in such cancer cells and, thus, inhibition of this kinase can lead to mitotic catastrophe and apoptosis, particularly if combined with DNA-damaging therapies. By contrast, aurora kinase A has essential roles in mitosis, and inhibitors of this protein results in cell-cycle arrest, preventing cell proliferation. Inhibitors of Notch have demonstrated antitumour effects in preclinical studies. Moreover, Delta-like protein 3 (DLL3), an inhibitory Notch ligand, is specifically upregulated in SCLC and can, therefore, be leveraged for selective tumour targeting with the antibody-drug conjugate rovalpituzumab tesirine (Rova-T). Inhibitors of the histone-lysine N-methyltransferase EZH2 (also known as enhancer of zeste homologue 2), the enzymatic histone-lysine N-methyltransferase subunit of the polycomb repressive complex 2 (PRC2) chromatin-remodelling machinery, can prevent chemoresistance and cell proliferation by counteracting epigenetic gene silencing, in particular, of schlafen family member 11 (SLFN11) -a protein that negatively regulates homologous recombination DNA repair. Poly [ADP-ribose] polymerase (PARP) inhibitors prevent the activation of DNA-repair proteins by PARP1 and trap this enzyme on DNA, which causes further DNA damage that can eventually result in cell death. APC, antigen-presenting cell; ASCL1, achaete-scute homologue 1 (also known as ASH-1); Chk1/2, checkpoint kinase 1/2; E2F1, transcription factor E2F1 (also known as retinoblastoma-associated protein 1); PAR, poly-ADP-ribosylation. ◀ 5-fluorouracil), topoisomerase inhibitors (camptothecin or doxorubicin), DNA-crosslinking agents (cisplatin or carboplatin), and PARP inhibitors, results in synergistic efficacy in TP53-deficient cervical, colon, pancreatic, and NSCLC cell lines [109] [110] [111] . As such, WEE1 is a promising target for SCLC therapy. Single-agent and combination studies of WEE1 inhibitors are now active in the clinic 112, 113 , and include studies in patients with relapsed and/or refractory SCLC (TABLE 1) . The role of TP53/RB1 status (that is, context dependency) and WEE1 expression as predictive biomarkers of response to WEE1-inhibitor therapy are of great interest, and remain an area of substantial controversy in preclinical studies 109, 111, 114, 115 .
The inhibitory Notch ligand DLL3. DLL3 is normally expressed in the developing CNS and has a key role in somitogenesis, the process by which somites (bi laterally paired blocks of mesoderm tissue) form along the anterior-posterior axis of the developing embryo 116, 117 . The Notch pathway has been implicated in regulating neuroendocrine versus epithelial-cell diff erentiation in embryonic lung development 118 and, more recently, in SCLC oncogenesis 12 . Notch activation is oncogenic in some tumour types; however, in neuroendocrine tumours, Notch signalling suppresses oncogenesis and tumour growth 12, 119 . Unlike other mammalian Notch family members, DLL3 is pre dominantly located in the Golgi apparatus and inhibits Notch 1 signalling in cis 120 . In high-grade neuroendocrine tumours, including SCLC, DLL3 is highly upregulated and aberrantly expressed on the cell surface, making it a potential therapeutic target 121 . Rovalpituzumab tesirine (Rova-T) is a novel, first-in-class, antibody-drug conjugate with high specificity for DLL3. Rova-T binds to DLL3 expressed on the cell surface, is internalized, and subsequent cleavage of a linker moiety releases the pyrrolobenzodiazepine (PBD) dimer cytotoxic payload from the anti-DLL3 antibody, resulting in tumour-specific DNA damage and cell death. PBDs, originally discovered in Streptomyces species of bacteria, are a class of sequence-selective, DNAminor-groove-binding agents that form covalent crosslinks between the N2 of guanine and the C11 position of the PBD 122, 123 . The resulting PBD-DNA adduct leads to replication-fork stalling, preventing DNA replication and causing cell-cycle arrest. PBDs are not inherently tumour specific; thus, conjugation of PBDs to an anti-DLL3 antibody enables a potential targeted therapeutic approach in SCLC. Preclinical findings demonstrated in vivo efficacy of Rova-T in patient-derived xenograft models of SCLC, with a strong correlation between the level of DLL3 expression and therapeutic activity 121 .
Results of the first-in-human phase I clinical trial of Rova-T in patients with recurrent metastatic SCLC and large-cell neuroendocrine lung cancers were 124 . Among the evaluable patients, 17% (11 of 65) had a confirmed objective response and 54% (35 of 65) had stable disease 124 . The median duration of response was 5.6 months (95% CI 2.5-8.3 months), median PFS was 3.1 months (95% CI 2.7-4.1 months), and the median overall survival was 4.6 months (95% CI 3.9-7.1 months) 124 . In patients with a high level of DLL3 expression (defined immunohistochemically as detectable protein expression in at least 50% of tumour cells), the ORR was 39% (10 of 26) and the disease-control rate (stable disease or objective response) was 89% (22 of 26) 124 . Most notably, among those patients with tissue available for protein analysis, responses were observed exclusively in those with a high DLL3 expression level 124 , further supporting the preclinical observation that the efficacy of Rova-T correlates with the level of DLL3 expression. In an exploratory ana lysis, median PFS was 4.5 months (95% CI 3.0-5.4 months) in the DLL3-high patient subgroup compared with 2.3 months (95% CI 1.3-3.3 months) in the DLL3-low subgroup; overall survival differences between the DLL3-high and DLL3-low subgroups were not reported 124 . These data support DLL3 as a candidate predictive biomarker for this therapy -potentially the first such biomarker in SCLC. These results, in a heavily pretreated patient population, seem promising; however, additional studies are needed to determine the clinical benefits of Rova-T treatment and multiple trials of this agent are ongoing (TABLE 1) , including an open-label, multicentre, phase II study of the efficacy of Rova-T in the third-line and later-line treatment of patients with DLL3-positive ES-SCLC (NCT02674568). Further proposed studies of Rova-T in patients with ES-SCLC encompass frontline treatment of DLL3-high disease (NCT02819999), maintenance therapy following firstline platinum-based chemotherapy (NCT03033511), and combination treatment with nivolumab -with or without ipilimumab -in the second-line setting (NCT03026166).
Aurora kinase. The aurora kinase family proteins have key roles in mitosis. Aurora kinase A is essential for centrosome function, spindle assembly, chromosome alignment, and mitotic entry 125 . Knockdown of aurora kinase A expression induces G2/M-phase arrest and thereby inhibits the proliferation of human SCLC cells 126 . Moreover, targeted drug screens have indicated that the neuroendocrine-low, variant subtype of SCLC with high MYC and NEUROD1 expression is vulnerable to aurora kinase inhibition, which strongly suppressed tumour progression when combined with chemotherapy in the aforementioned mouse model of this disease subtype 49 . Alisertib, an investigational, orally administered, selective inhibitor of aurora kinase A, has preclinical therapeutic activity across multiple tumour types 127 . In a multicentre phase I/II study of this agent in patients with various solid tumours 128 , a recommended phase II dose and schedule was defined, and dose-limiting toxicities, including neutropenia, leukopenia, and anaemia, were noted. In a phase II study expansion cohort comprising patients with relapsed and/or refractory SCLC, single-agent alisertib therapy resulted in an ORR of 21% (10 of 48 patients; 95% CI 10-35) 128 . Furthermore, in a randomized phase II study of paclitaxel plus either alisertib or placebo in the second-line treatment of patients with SCLC, the ORR was 22% in the experimental arm (20 of 89) and 18% in the control arm (16 of 89) ; the median PFS was 101 days versus 66 days (HR 0.71,95% CI 0.51-0.99; P = 0.04) 129 . Further clinical investigations are needed to better study and optimize the therapeutic utility of this compound in SCLC.
Immunotherapy for SCLC Escape from immune surveillance is a well-recognized feature of cancer 130 . The development of therapies to enhance antitumour immune responses -particularly antagonistic antibodies targeting the inhibitory immune-checkpoint proteins cytotoxic T-lymphocyteassociated protein 4 (CTLA-4), programmed cell death protein 1 (PD-1), or its ligand PD-L1 (FIG. 2) -has led to exciting new treatment options for patients, across multiple tumour types 131, 132 . The high mutational burden of SCLCs, resulting in a large number of potential tumour-specific antigens, has raised hope that immunotherapy might be effective in this disease. At present, only limited data have been reported on immune-checkpoint blockade in patients with SCLC, although a number of clinical trials of this promising therapeutic approach are underway (TABLE 2) .
CTLA-4.
Ipilimumab, a fully human monoclonal IgG1, binds to CTLA-4 expressed by T cells and blocks the interaction of this receptor with its ligands CD80 and CD86 on antigen-presenting cells (FIG. 2) . Upon ligand binding, CTLA-4 transmits signals that suppress T-cell priming, and thus blockade of this interaction using ipilimumab can promote T-cell activation and an anti cancer immune response 133 . In a randomized phase II study, investigators evaluated the activity of ipilimumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin alone in patients with ES-SCLC 134 ; 133 patients with previously untreated ES-SCLC were randomly assigned (1:1:1) to receive either concurrent ipilimumab and chemotherapy, phased-ipilimumab and chemotherapy, or the control regimen of chemotherapy alone. This study was not stratified by PD-L1 expression status, and the immune-related response criteria (irRC) were used to assess response to therapy. The irRC are modified RECIST criteria that capture the unique tumour response patterns observed with immunotherapy, including regression of index lesions coincident with the appearance of new lesions, and initial progression followed by tumour stabilization or a decrease in tumour burden 135 . The phased administration of ipilimumab in combination with paclitaxel and carboplatin, after induction with the same chemotherapy regimen plus placebo, resulted in an improvement in immune-related PFS (as per the iRC) compared with that observed with induction and maintenance chemotherapy plus placebo (HR 0.64; P = 0.03); however, no significant improvement in PFS (HR 0.93; P = 0.37) or overall survival (HR 0.75; P = 0.13) was demonstrated 134 . Moreover, induction therapy with concurrent ipilimumab plus chemotherapy with maintenance chemotherapy plus placebo did not improve patient outcomes 134 . In the same setting, a follow-up phase III trial of phased ipilimumab in combination with moreconventional first-line chemotherapy (comprising etoposide and a platinum-based agent) versus the same chemotherapy regimen plus placebo was negative for its primary end point of overall survival: median 11.0 months versus 10.9 months (HR 0.94, 95% CI 0.81-1.09; P = 0.38) 136 . Furthermore, ipilimumab was associated with a high frequency of some toxicities, including diarrhoea, rash, and colitis 136 .
PD-1 and PD-L1 blockade. PD-L1 is expressed on a range of cell types, including some neoplastic and non-neoplastic cells within tumours, and interaction of this protein with PD-1 on T cells results in local suppression of T-cell activation and cytotoxicity, and promotes T-cell exhaustion (FIG. 2) . Nivolumab, a fully human IgG4, binds to PD-1 and blocks its interaction with PD-L1, which can reinvigorate T-cell activity and potentially unleash suppressed antitumour immunity. Although ipilimumab alone did not improve chemo therapy responsiveness of patients with SCLC 136 , preclinical data from the melanoma literature suggests that combined PD-1 and CTLA-4 blockade can synergistically enhance activation of tumour-specific T cells and antitumour activity through complementary mechanisms 137 . Outcome data from CheckMate 032, a multicentre, open-label, phase I/II trial of nivolumab with or without ipilimumab in patients with recurrent ES-SCLC 138 , were reported in 2016. The study investigators enrolled 216 patients, including 98 patients treated with nivolumab alone and the remainder with alternative schedules incorporating both nivolumab and ipilimumab. The toxicity profiles were similar to those observed in prior studies of these agents, including grade 3-4 events in 13% of patients receiving nivolumab alone, and between 19% and 30% of patients receiving nivolumab and ipilimumab 138 . The ORRs were 10% in the nivolumab arm and 19-23% in the combination arms, translating into an encouraging 1-year survival of 33% and 35-43%, respectively 138 . These results have led to the incorporation of the nivolumab and ipilimumab combination as a National Comprehensive Cancer Network (NCCN) guideline recommendation for the second-line treatment of ES-SCLC 20 . However, the efficacy of checkpoint inhibitors in patients with SCLC needs to be confirmed in randomized trials, and these treatments have not been formally approved for the treatment of SCLC in the USA or elsewhere and, therefore, remain experimental. Potential toxicity remains an ongoing concern with combination immunotherapy, and physicians should have a substantive discussion with their patients regarding potential risks and benefits of treatment. Close monitoring of the endocrine axis and early detection of immune-related adverse events, such as colitis and pneumonitis, are critical because patients can benefit from early intervention with high-dose steroids and/or drug discontinuation. A high mutational burden has been identified as a potential predictor of effective immuno therapy 139 ; however, despite the fact that SCLCs have among the highest mutational burdens of all tumour types 11 , the clinical efficacy of checkpoint inhibitors in this disease seems to be far less pronounced than would be expected based on the experiences in other highly mutated cancers, such as melanoma and NSCLC. In stark contrast to other tumour types, SCLCs rarely express PD-L1, which might at least partially explain this disparity.
In an immunohistochemical analysis of arc hival formalin-fixed paraffin-embedded SCLC specimens using two different assays (VENTANA PD-L1 (SP142) and 28-8 pharmDx) 140 , the overall prevalence of PD-L1 expression in tumour cells was found to be low (16.5%) and was not markedly different between LS-SCLC and ES-SCLC samples. Importantly, PD-L1 positivity does not seem to be predictive of immunotherapy response in this setting 138 . Work to define predictive biomarkers of immunotherapy response and the characteristics of the SCLC immune microenvironment is ongoing. In addition, multiple clinical trials of combination strategies to bolster the efficacy of immune-checkpoint inhibition are underway in patients with SCLC (TABLE 2) .
CD47
. CD47 is a cell-surface molecule that inhibits activation and phagocytic activity of macrophages by engaging signal-regulatory protein α 141 (SIRPα ; FIG. 2 ). In fact, CD47 is involved in regulating a wide variety of physiological processes, including platelet and neutrophil activation, T-cell function, vascular signalling by nitric oxide, suppression of dendritic cell activity, and inhibition of monocyte activation 142 . This protein is expressed on many normal cells, but is highly upregulated on the surface of human SCLC cells and has been implicated in immune escape by tumours 143 . In particular, disruption of the interaction of CD47 and SIRPα, using anti-CD47 antibodies, induced macrophagemediated phagocytosis of human SCLC cell lines in vitro and in mouse xenograft models 143 . Moreover, CD47 blockade has been shown to trigger T-cell-mediated destruction of immunogenic tumours 144 , and thus combination strategies with immune-checkpoint blockade might enhance the antitumour effects of anti-CD47 antibodies. Clinical exploration of CD47/SIRPα inhibition as a therapeutic strategy for SCLC is expected to begin in 2017.
Conclusions
Large-scale genomic, proteomic, and transcriptomic analyses have led to the identification of new druggable targets in SCLC (FIG. 2) . PARP1, EZH2, WEE1, and DLL3 are all examples of novel targets implicated as vulnerabilities, and tractable therapeutic opportunities, in SCLC; drugs for each of these targets are under active clinical investigation. Rapid progress in the field of immuno-oncology has similarly opened a door to new treatment options. Treatment with the combination of ipilimumab and nivolumab is now NCCNrecommended for patients with recurrent SCLC after platinum-based therapy. Nevertheless, the immune microenvironment of SCLC seems to be distinct from that of other solid tumours, with alternative targets, such as CD47, coming to the fore. Defining predictive biomarkers for targeted therapies and optimizing activation of antitumour immune response in SCLC are areas of intensive ongoing investigation. The progress made in defining novel therapeutic targets in SCLC has renewed hope for advances in combatting this re calcitrant disease. Several ongoing and upcoming clinical trials will test whether these new insights into tumour biology can be successfully translated into major therapeutic breakthroughs in what has been a singularly challenging and deadly disease.
